GLATIRAMER ACETATE

Glatiramer acetate was initially approved by the United States Food and Drug Administration (FDA) in 1996.

Glatiramer acetate is primarily used for the treatment of multiple sclerosis (MS), specifically in individuals with relapsing-remitting multiple sclerosis (RRMS).

Glatiramer acetate is primarily administered via subcutaneous injection. The dosage of this medication can vary depending on the specific formulation and the individual's condition.

Glatiramer acetate may cause several side effects, ranging from common to less common reactions. Common side effects that individuals may experience include redness, pain, or swelling at the injection site, which rotating injection sites can manage. Flushing, a warm, red, or tingly feeling under the skin, and shortness of breath are also among the common side effects that have been reported. Additionally, some individuals may experience heart palpitations, manifesting as a rapid, strong, or irregular heartbeat.

Glatiramer acetate may lead to chest pain or heart palpitations. Patients with a history of respiratory conditions may have respiratory symptoms, including shortness of breath. It may affect the immune system, potentially increasing the risk of infections.

Individuals with pre-existing cardiovascular conditions should use Glatiramer acetate with caution. Patients with compromised immune function or those taking immunosuppressive medications should use this medication with caution and under the guidance of a healthcare provider.

Individuals with a known hypersensitivity to Glatiramer acetate should avoid using this medication to prevent potential allergic reactions. Injection site reactions, including redness, pain, or swelling, are common and can be managed by rotating injection sites. It is important to be aware that it may lead to cardiovascular effects such as chest pain or heart palpitations, particularly in individuals with pre-existing cardiovascular conditions. Patients with respiratory conditions need close monitoring, as the medication may cause respiratory symptoms, including shortness of breath. Considering its impact on the immune system, individuals with compromised immune function or those taking immunosuppressive medications should exercise caution while using them. Regular monitoring of kidney function is important for patients with renal impairment, as the kidneys primarily excrete this medication. It is important to discuss any pre-existing conditions, allergies, or concerns with a healthcare provider to ensure this medication's safe and appropriate use. Regular follow-up appointments can help monitor the individual's response to the medication and address any potential issues or side effects.

Teva Neuroscience, Inc., [Revised on Dec 2019] [Accessed on 8th Nov 2023], https://www.copaxonehcp.com/globalassets/copaxone/prescribing-information.pdf Teva Pharmaceuticals Ltd, Electronic Medicines Compendium (EMC), [Revised on 16 Mar 2022] [Accessed on 8th Nov 2023], https://www.medicines.org.uk/emc/product/7046/smpc#gref Teva Pharma B.V.Food and Drug Administration (FDA) [Revised on Apr 2016] [Accessed on 8th Nov 2023], https://www.accessdata.fda.gov/drugsatfda_docs/psg/Glatiramer%20acetate_subcutaneous%20Injection_NDA%20020622_RV07-18.pdf J.P. Leach, R.J. Davenport, Neurological disease, Davidson’s Principles and Practice of Medicine, 22nd Edition, 2014, 1137-1230.